Applied BioCode (6598) - Total Assets
Based on the latest financial reports, Applied BioCode (6598) holds total assets worth NT$1.03 Billion TWD (≈ $32.48 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Applied BioCode (6598) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Applied BioCode - Total Assets Trend (2012–2024)
This chart illustrates how Applied BioCode's total assets have evolved over time, based on quarterly financial data. Check Applied BioCode earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Applied BioCode - Asset Composition Analysis
Current Asset Composition (December 2024)
Applied BioCode's total assets of NT$1.03 Billion consist of 90.9% current assets and 9.1% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 49.9% |
| Accounts Receivable | NT$45.02 Million | 3.7% |
| Inventory | NT$190.07 Million | 15.7% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$1.80 Million | 0.2% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Applied BioCode's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Applied BioCode worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Applied BioCode's current assets represent 90.9% of total assets in 2024, an increase from 68.7% in 2012.
- Cash Position: Cash and equivalents constituted 49.9% of total assets in 2024, down from 53.4% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 15.7% of total assets.
Applied BioCode Competitors by Total Assets
Key competitors of Applied BioCode based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.62 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
Applied BioCode - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.96 | 11.30 | 13.12 |
| Quick Ratio | 6.41 | 9.37 | 11.76 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$767.13 Million | NT$1.03 Billion | NT$943.27 Million |
Applied BioCode - Advanced Valuation Insights
This section examines the relationship between Applied BioCode's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.60 |
| Latest Market Cap to Assets Ratio | 0.07 |
| Asset Growth Rate (YoY) | 22.3% |
| Total Assets | NT$1.21 Billion |
| Market Capitalization | $79.03 Million USD |
Valuation Analysis
Below Book Valuation: The market values Applied BioCode's assets below their book value (0.07x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Applied BioCode's assets grew by 22.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Applied BioCode (2012–2024)
The table below shows the annual total assets of Applied BioCode from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.21 Billion ≈ $38.28 Million |
+22.32% |
| 2023-12-31 | NT$993.21 Million ≈ $31.29 Million |
-18.08% |
| 2022-12-31 | NT$1.21 Billion ≈ $38.20 Million |
+18.99% |
| 2021-12-31 | NT$1.02 Billion ≈ $32.10 Million |
-16.97% |
| 2020-12-31 | NT$1.23 Billion ≈ $38.66 Million |
+70.68% |
| 2019-12-31 | NT$719.01 Million ≈ $22.65 Million |
+39.87% |
| 2018-12-31 | NT$514.07 Million ≈ $16.20 Million |
+52.62% |
| 2017-12-31 | NT$336.83 Million ≈ $10.61 Million |
-29.65% |
| 2016-12-31 | NT$478.77 Million ≈ $15.08 Million |
+53.95% |
| 2015-12-31 | NT$310.99 Million ≈ $9.80 Million |
-12.31% |
| 2014-12-31 | NT$354.66 Million ≈ $11.17 Million |
+82.29% |
| 2013-12-31 | NT$194.56 Million ≈ $6.13 Million |
-26.02% |
| 2012-12-31 | NT$262.99 Million ≈ $8.29 Million |
-- |
About Applied BioCode
Applied BioCode Corporation designs, develops, and commercializes multiplex diagnostic testing products in California. Its products include the BioCode MDx 3000 system, an automated molecular diagnostic system that automates the detection steps, PCR amplification, and hybridization and target capture; and the BioCode 2500 analyzer, a system that reads each barcode and quantifies the BMB target us… Read more